The refinancing addresses upcoming maturities (EUR 500M Dec 2026 and $600M Feb 2027) and extends the company's debt maturity profile. Monitor the Q4 2026 earnings for updated leverage ratios and any acquisition announcements that may utilize the remaining proceeds.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $103.21entry
- T+1 · 21h ago −1.74%α +0.17% · $101.41
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Zimmer Biomet completed two concurrent debt offerings on November 12, 2026: EUR 500 million of 4.375% notes due 2033 and $500 million of 5.850% notes due 2036, with combined net proceeds of approximately $1.05 billion. The proceeds are earmarked for general corporate purposes including refinancing near-term maturities (EUR 500M 2.425% notes due Dec 2026 and/or $600M 4.700% notes due Feb 2027), share repurchases, and acquisitions. This is a routine debt refinancing and capital management move, not a distressed raise.
Key Facts
- EUR 500 million 4.375% notes due 2033 issued at 99.594% of par, net proceeds ~EUR 496.4M (~$556.9M)
- $500 million 5.850% notes due 2036 issued at 99.343% of par, net proceeds ~$495.1M
- Both offerings closed on November 12, 2026, with combined net proceeds of approximately $1.05 billion
- Proceeds to be used for general corporate purposes including potential repayment of EUR 500M 2.425% notes due Dec 2026 and/or $600M 4.700% notes due Feb 2027, share repurchases, and acquisitions
- Neither offering was contingent on the other; both were priced on November 5, 2026
- Company reported Q3 2026 results with modest revenue growth and raised full-year guidance five days prior to pricing
Financial Impact
Combined net proceeds of approximately $1.05 billion from two debt offerings, primarily for refinancing near-term maturities and general corporate purposes
Risk Factors
- Increased total debt outstanding by approximately $1.05 billion, though partially offset by repayment of maturing notes
- Higher blended interest cost: new notes carry 4.375% and 5.850% coupons vs. maturing notes at 2.425% and 4.700%
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-458323 |
| Document: d118853dex42.htm | 0001193125-26-458323 |
| Document: d118853dex12.htm | 0001193125-26-458323 |
Track record
17 reports on ZBH
3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +8.74% at T+60 after the Apr 28, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 3/10 Viewing Entry $103.21 Now $101.41 −1.74% settles Nov 20
- Nov 9, 20267d ago 424B5 Neutral 3/10 Entry $107.32 Now $101.41 −5.51% settles Nov 17
- Nov 9, 20267d ago 424B5 Neutral 3/10 Entry $107.32 Now $101.41 −5.51% settles Nov 17
- Nov 5, 202611d ago 424B5 Neutral 3/10 Entry $106.85 to $104.56 Now $101.41 −5.09% ▼ −2.14% −5.43% vs SPY
- Nov 5, 202611d ago 424B5 Neutral 2/10 Entry $106.85 to $104.56 Now $101.41 −5.09% ▼ −2.14% −5.43% vs SPY
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $110.15 to $107.47 Now $101.41 −7.93% ▼ −2.43% −1.52% vs SPY
- Oct 26, 202621d ago Institutional Cluster Bearish 4/10 Entry $97.44 to $94.52 Now $101.41 −4.07% ▲ +3.00% +1.74% vs SPY
- Oct 21, 202627d ago Court Ruling Bearish 6/10 Entry $98.81 to $97.47 Now $101.41 −2.63% ▲ +1.36% +2.06% vs SPY
- Sep 15, 20268w ago Insider Cluster Neutral 3/10 Entry $96.53 to $90.64 Now $101.41 +5.06% ▼ −6.10% −8.17% vs SPY
- Sep 2, 202610w ago Court Ruling Neutral 2/10 Entry $98.66 to $93.24 Now $101.41 +2.79% ▼ −5.49% −4.34% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers